PepGen Inc. (PEPG) Stock Analysis and Metrics

PepGen

NASDAQ: PEPG

$1.92 ▼ -0.18 (-8.57%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap145.09 Mn

P/E-1.88

Div. Yield0.00

Add ratio to table…

About

PepGen Inc. is a clinical stage biotechnology company focused on developing next generation oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases. The company’s proprietary Enhanced Delivery Oligonucleotide, or EDO, platform uses cell penetrating peptides to improve the uptake and activity of conjugated oligonucleotide drugs. The EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery, and in preclinical studies they have shown the ability to transport oligonucleotides into a broad range of target tissues including smooth, skeletal and cardiac muscle. Its lead product candidate, PGN EDODM1, is designed to treat myotonic dystrophy type 1 by binding to pathogenic CUG repeats in DMPK mRNA and liberating the splicing factor MBNL1, thereby correcting downstream mis splicing without degrading the DMPK transcript. PepGen Inc. is advancing PGN EDODM1 through clinical trials and aims to expand the EDO platform to additional high need diseases.

PepGen Inc. currently does not have product revenue and relies on equity financing to fund its research and development activities. The company completed an initial public offering in May 2022, which provided proceeds that support ongoing clinical programs and operational expenses. PepGen Inc. has not yet commercialized any therapy and therefore generates no product sales revenue at this stage.

PepGen Inc. occupies a niche within the oligonucleotide therapeutics sector, competing with other companies developing treatments for myotonic dystrophy type 1 such as Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Arrowhead Pharmaceuticals and Sarepta Therapeutics. Its competitive advantage lies in the EDO platform, which couples a proprietary cell penetrating peptide with a phosphorodiamidate morpholino oligomer to enhance nuclear delivery in skeletal muscle while avoiding knock down of the DMPK transcript, a mechanism that may reduce the risk of haploinsufficiency. The company also benefits from orphan drug and Fast Track designations from the U. S. FDA and orphan medicinal product designation from the EMA for PGN EDODM1. These regulatory distinctions highlight the unmet medical need in DM1 and may facilitate faster development and review pathways. PepGen Inc. believes its approach offers a differentiated mechanism that directly addresses the genetic defect without altering overall DMPK levels, setting it apart from strategies that aim to degrade the transcript.

PepGen Inc. intends to treat patients suffering from myotonic dystrophy type 1, a rare genetic disorder that affects skeletal, cardiac and smooth muscle and is associated with central nervous system symptoms. The disease prevalence is estimated at approximately one in eight thousand individuals worldwide, with tens of thousands of patients in the United States, Europe and Japan. Its prospective customers include individuals diagnosed with DM1, their treating physicians, and healthcare systems that provide coverage for orphan therapies. The company expects that successful treatment would address the underlying molecular defect and potentially improve muscle function and quality of life for this patient population.

Investment Thesis

▲ Bull case

PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which utilizes cell-penetrating peptides to enhance the cellular uptake and activity of oligonucleotide therapeutics, represents a significant technological advancement over traditional antisense oligonucleotide approaches. The Phase 1 FREEDOM-DM1 trial demonstrated unprecedented splicing correction levels after a single dose, achieving 12.3%, 29.1%, and 53.7% at 5 mg/kg, 10 mg/kg, and 15 mg/kg respectively, with greater than dose-proportional increases in muscle tissue concentration. This robust target engagement, particularly the observation of meaningful splicing correction at the lowest tested dose, suggests a high therapeutic index and potential for best-in-class efficacy in myotonic dystrophy type 1 (DM1), a disease with no approved disease-modifying therapies. The differentiated mechanism of PGN-EDODM1—which binds to pathogenic CUG repeats without degrading the DMPK transcript—allows the endogenous gene to maintain its normal function while liberating MBNL1 to correct downstream mis-splicing, offering a potential advantage over knockdown-based approaches that may disrupt essential gene functions. The Orphan Drug and Fast Track Designations from the FDA, coupled with EMA Orphan Designation, provide regulatory incentives including tax credits, market exclusivity, and accelerated development pathways, de-risking the path to approval. Despite the partial clinical hold on the U.S. arm of FREEDOM2, PepGen has successfully opened the trial in New Zealand, Australia, and South Korea, with patients in the UK and Canada already dosed at the 10 mg/kg level following an independent Data Safety Monitoring Board's recommendation to escalate dose, indicating confidence in the drug's safety profile from existing data. The company's cash position of $148.5 million as of December 31, 2025, is sufficient to fund operations into the second half of 2027, providing ample runway to complete the 10 mg/kg and 12.5 mg/kg cohorts of FREEDOM2 and advance other pipeline candidates without near-term financing pressure. The upcoming presentation of individual patient mis-splicing data from PGN-EDODM1 at the late-breaking oral session of IDMC-15 in May 2026, along with the anticipated readout of the 10 mg/kg FREEDOM2 cohort in the second half of 2026, represents near-term catalysts that could validate the therapeutic potential and drive re-rating of the stock if data confirms sustained functional benefit alongside the strong splicing signals already observed. PepGen's focus on severe neuromuscular and neurological diseases with high unmet need positions it to capture significant value if its EDO platform demonstrates translatable efficacy beyond DM1, with the platform's versatility enabling expansion into other genetic diseases where delivery has been a limiting factor for oligonucleotide therapies.

PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which utilizes cell-penetrating peptides to enhance the cellular uptake and activity of oligonucleotide therapeutics, represents a significant technological advancement over traditional antisense oligonucleotide approaches. The Phase 1 FREEDOM-DM1 trial demonstrated unprecedented splicing correction levels after a single dose, achieving 12.3%, 29.1%, and 53.7% at 5 mg/kg, 10 mg/kg, and 15 mg/kg respectively, with greater than dose-proportional increases in muscle tissue concentration. This robust target engagement, particularly the observation of meaningful splicing correction at the lowest tested dose, suggests a high therapeutic index and potential for best-in-class efficacy in myotonic dystrophy type 1 (DM1), a disease with no approved disease-modifying therapies. The differentiated mechanism of PGN-EDODM1—which binds to pathogenic CUG repeats without degrading the DMPK transcript—allows the endogenous gene to maintain its normal function while liberating MBNL1 to correct downstream mis-splicing, offering a potential advantage over knockdown-based approaches that may disrupt essential gene functions. The Orphan Drug and Fast Track Designations from the FDA, coupled with EMA Orphan Designation, provide regulatory incentives including tax credits, market exclusivity, and accelerated development pathways, de-risking the path to approval. Despite the partial clinical hold on the U.S. arm of FREEDOM2, PepGen has successfully opened the trial in New Zealand, Australia, and South Korea, with patients in the UK and Canada already dosed at the 10 mg/kg level following an independent Data Safety Monitoring Board's recommendation to escalate dose, indicating confidence in the drug's safety profile from existing data. The company's cash position of $148.5 million as of December 31, 2025, is sufficient to fund operations into the second half of 2027, providing ample runway to complete the 10 mg/kg and 12.5 mg/kg cohorts of FREEDOM2 and advance other pipeline candidates without near-term financing pressure. The upcoming presentation of individual patient mis-splicing data from PGN-EDODM1 at the late-breaking oral session of IDMC-15 in May 2026, along with the anticipated readout of the 10 mg/kg FREEDOM2 cohort in the second half of 2026, represents near-term catalysts that could validate the therapeutic potential and drive re-rating of the stock if data confirms sustained functional benefit alongside the strong splicing signals already observed. PepGen's focus on severe neuromuscular and neurological diseases with high unmet need positions it to capture significant value if its EDO platform demonstrates translatable efficacy beyond DM1, with the platform's versatility enabling expansion into other genetic diseases where delivery has been a limiting factor for oligonucleotide therapies.

▼ Bear case

PepGen's lead candidate PGN-EDODM1 faces substantial clinical and regulatory risks underscored by the U.S. Food and Drug Administration's partial clinical hold on the FREEDOM2-DM1 trial, which specifically questions previously submitted preclinical pharmacology and toxicology studies. While the company states the hold does not cite concerns from blinded Phase 1 FREEDOM clinical data, the need to submit additional analyses—including newly unblinded FREEDOM data—indicates unresolved preclinical safety concerns that could delay or derail development, particularly given the hold's focus on foundational toxicology data required for IND advancement. The absence of any U.S. patient enrollment in FREEDOM2 prior to the hold, combined with reliance on international sites (UK, Canada, South Korea, Australia, New Zealand) for ongoing dosing, introduces significant complexity in trial execution, including variability in standard of care, regulatory oversight, and patient demographics, which could compromise data consistency and regulatory acceptability for a potential U.S. NDA submission. Despite positive splicing biomarker signals in the Phase 1 FREEDOM study, there remains no evidence of meaningful functional improvement in patients, and the translation of splicing correction to clinically relevant endpoints—such as muscle strength, motor function, or quality of life—is unproven and carries significant risk of failure, especially given the heterogeneous nature of DM1 and the lack of validated functional biomarkers in the disease. The company's financial statements reveal a net loss of $89.7 million for the full year 2025 and $17.8 million for Q1 2026, with operating expenses remaining elevated at $18.9 million in the most recent quarter despite a sequential decline from Q4 2025, reflecting the high cash burn inherent in clinical-stage biotechnology; while the current cash runway extends to mid-2027, any delay in FREEDOM2 readouts or need for additional preclinical work due to the FDA hold could accelerate cash consumption and necess dilutive financing before key data milestones. PepGen's pipeline remains heavily concentrated on PGN-EDODM1 for DM1, with no other clinical-stage candidates disclosed, creating binary dependency on a single program in a single indication; the lack of diversification increases vulnerability to setbacks in DM1 development, and the platform's applicability to other neurological diseases remains unvalidated in clinical settings. The competitive landscape for oligonucleotide therapies in neuromuscular diseases is intensifying, with multiple approaches (including siRNA, antisense oligonucleotides, and CRISPR-based strategies) being pursued by larger pharmaceutical companies with greater resources, potentially diminishing PepGen's first-mover advantage even if PGN-EDODM1 succeeds, and raising concerns about long-term commercial viability and pricing power in a niche orphan disease market with limited patient pools (~115,000 in U.S. and EU) and uncertain willingness-to-pay for disease-modifying therapies.

PepGen's lead candidate PGN-EDODM1 faces substantial clinical and regulatory risks underscored by the U.S. Food and Drug Administration's partial clinical hold on the FREEDOM2-DM1 trial, which specifically questions previously submitted preclinical pharmacology and toxicology studies. While the company states the hold does not cite concerns from blinded Phase 1 FREEDOM clinical data, the need to submit additional analyses—including newly unblinded FREEDOM data—indicates unresolved preclinical safety concerns that could delay or derail development, particularly given the hold's focus on foundational toxicology data required for IND advancement. The absence of any U.S. patient enrollment in FREEDOM2 prior to the hold, combined with reliance on international sites (UK, Canada, South Korea, Australia, New Zealand) for ongoing dosing, introduces significant complexity in trial execution, including variability in standard of care, regulatory oversight, and patient demographics, which could compromise data consistency and regulatory acceptability for a potential U.S. NDA submission. Despite positive splicing biomarker signals in the Phase 1 FREEDOM study, there remains no evidence of meaningful functional improvement in patients, and the translation of splicing correction to clinically relevant endpoints—such as muscle strength, motor function, or quality of life—is unproven and carries significant risk of failure, especially given the heterogeneous nature of DM1 and the lack of validated functional biomarkers in the disease. The company's financial statements reveal a net loss of $89.7 million for the full year 2025 and $17.8 million for Q1 2026, with operating expenses remaining elevated at $18.9 million in the most recent quarter despite a sequential decline from Q4 2025, reflecting the high cash burn inherent in clinical-stage biotechnology; while the current cash runway extends to mid-2027, any delay in FREEDOM2 readouts or need for additional preclinical work due to the FDA hold could accelerate cash consumption and necess dilutive financing before key data milestones. PepGen's pipeline remains heavily concentrated on PGN-EDODM1 for DM1, with no other clinical-stage candidates disclosed, creating binary dependency on a single program in a single indication; the lack of diversification increases vulnerability to setbacks in DM1 development, and the platform's applicability to other neurological diseases remains unvalidated in clinical settings. The competitive landscape for oligonucleotide therapies in neuromuscular diseases is intensifying, with multiple approaches (including siRNA, antisense oligonucleotides, and CRISPR-based strategies) being pursued by larger pharmaceutical companies with greater resources, potentially diminishing PepGen's first-mover advantage even if PGN-EDODM1 succeeds, and raising concerns about long-term commercial viability and pricing power in a niche orphan disease market with limited patient pools (~115,000 in U.S. and EU) and uncertain willingness-to-pay for disease-modifying therapies.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,785.72 Bn	-32.10 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,895.57 Bn	0.00 Bn	56,599.40	0.11 Bn
3	ONC	BeOne Medicines Ltd.	471.35 Bn	0.00 Bn	82.13	0.96 Bn
4	NCNA	NuCana plc	279.75 Bn	0.00 Bn	-	-
5	VRTX	Vertex Pharmaceuticals Inc / Ma	120.24 Bn	0.00 Bn	9.84	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.80 Bn	0.00 Bn	4.54	1.99 Bn
7	BLTE	Belite Bio, Inc	62.51 Bn	367.72 Bn	-	-
8	ARGX	Argenx Se	57.38 Bn	0.00 Bn	12.31	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password